These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2692427)

  • 21. Plasmodium falciparum: induction of biologically active antibodies to gp195 is dependent on the choice of adjuvants.
    Hui GS; Chang SP
    Exp Parasitol; 1992 Aug; 75(1):155-7. PubMed ID: 1639161
    [No Abstract]   [Full Text] [Related]  

  • 22. The development of molecular vaccines against malaria sporozoites.
    Ballou WR; Young JF; Cryz SJ; Sadoff JC
    Adv Exp Med Biol; 1989; 251():295-313. PubMed ID: 2692428
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of recombinant DNA Plasmodium falciparum sporozoite vaccine?
    Grove DI
    Lancet; 1987 Jul; 2(8552):220. PubMed ID: 2885674
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.
    Quakyi IA; Otoo LN; Pombo D; Sugars LY; Menon A; De Groot AS; Johnson A; Alling D; Miller LH; Good MF
    Am J Trop Med Hyg; 1989 Aug; 41(2):125-34. PubMed ID: 2672834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and evaluation of a multistage combination vaccine against malaria.
    Zhang Q; Xue X; Qu L; Pan W
    Vaccine; 2007 Mar; 25(11):2112-9. PubMed ID: 17241708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults.
    Stürchler D; Berger R; Etlinger H; Fernex M; Matile H; Pink R; Schlumbom V; Just M
    Vaccine; 1989 Oct; 7(5):457-61. PubMed ID: 2479187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Luo K; Zavala F; Gordy J; Zhang H; Markham RB
    Vaccine; 2017 Apr; 35(18):2358-2364. PubMed ID: 28342669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
    Teo WH; Nurul AA; Norazmi MN
    Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
    Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
    J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards a malaria vaccine: what is in sight?
    del Giudice G
    Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
    [No Abstract]   [Full Text] [Related]  

  • 33. A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice.
    Arama C; Waseem S; Fernández C; Assefaw-Redda Y; You L; Rodriguez A; Radošević K; Goudsmit J; Kaufmann SH; Reece ST; Troye-Blomberg M
    Vaccine; 2012 Aug; 30(37):5578-84. PubMed ID: 21983157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites.
    Calvo-Calle JM; Oliveira GA; Nardin EH
    J Immunol; 2005 Dec; 175(11):7575-85. PubMed ID: 16301667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a sporozoite malaria vaccine.
    Nussenzweig V; Nussenzweig RS
    Am J Trop Med Hyg; 1986 Jul; 35(4):678-88. PubMed ID: 2425647
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens.
    Rawlings DJ; Kaslow DC
    J Exp Med; 1992 Nov; 176(5):1483-7. PubMed ID: 1383389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
    Mehrizi AA; Ameri Torzani M; Zakeri S; Jafary Zadeh A; Babaeekhou L
    Parasite Immunol; 2018 Jul; 40(7):e12538. PubMed ID: 29799636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.